Alnylam Pharmaceuticals (ALNY) shares soared 11.8% in the last trading session to close at $283.34. The move was backed by solid volume with far more shares changing hands than in a normal session.

Scotiabank raised the firm’s price target on Alnylam (ALNY) to $338 from $300 and keeps an Outperform rating on the shares.The firm expects Amvuttra, the first transthyretin silencer to enter ...

Also, Alnylam wins an important approval for ATTR-CM. The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to ...

The Food and Drug Administration cleared Alnylam Pharmaceuticals’ treatment for a progressive heart condition Thursday, setting it up to compete with therapies from BridgeBio and Pfizer.

For the quarter ended December 2024, Alnylam Pharmaceuticals (ALNY) reported revenue of $593.17 million, up 34.9% over the same period last year. EPS came in at $0.06, compared to -$1.10 in the ...

Alnylam's Amvuttra first to treat both nerve and heart forms of ATTR-CM Pricing strategy crucial for Amvuttra's market share against oral options Alnylam is banking on the success of the drug ...

Analysts see drug as potential new standard of care in ATTR-CM Label includes benefit of reducing urgent heart failure visits March 21 (Reuters) - Alnylam Pharmaceuticals' (ALNY.O), opens new tab ...

FDA approved Alnylam's Amvuttra for ATTR-CM, making it the first treatment cleared for both ATTR-CM and hATTR-PN in adults. In trials, Amvuttra cut mortality risk by 36% through 42 months and ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability. Alnylam Pharmaceuticals ...

US FDA Expands Approval for Alnylam's Drug to Treat Rare Heart Disease By Bhanvi Satija and Sneha S K (Reuters) -U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and ...